Summit Therapeutics Inc. Share Price

Stocks

SMMT

US86627T1088

Biotechnology & Medical Research

Market Closed - 21:00:00 05/10/2026 BST 5-day change 1st Jan Change
17.27 USD +3.07% Intraday chart for Summit Therapeutics Inc. +11.56% -1.26%

Valuation: Summit Therapeutics Inc.

Market Cap 10.42B 13.78B 12.29B 11.45B 19.62B 1,327B 19.77B 138B 53.83B 677B 51.72B 50.6B 2,177B P/E 2026 *
-15x
P/E 2027 * -14.9x
Enterprise Value 9.95B 13.16B 11.74B 10.93B 18.74B 1,267B 18.88B 132B 51.4B 647B 49.39B 48.32B 2,079B EV / Sales 2026 *
3,390x
EV / Sales 2027 * 244x
Free-Float
19.11%
Yield 2026 *
-
Yield 2027 * -
09-22 Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026 CI
09-15 Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients CI
09-14 Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit MT
09-09 Summit Therapeutics Shares Rise After Upgrade From Jefferies MT
09-09 Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 MT
08-26 Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release MT
08-26 US Equity Futures Mostly Flat Pre-Bell as Traders Weigh Inflation Data, Await Nvidia Results MT
08-26 Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints MT
08-26 Summit Therapeutics Reports Positive Topline Results From Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer CI
08-25 Wall Street Wants Receipts Zonebourse
08-25 Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines… Zonebourse
08-12 Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC MT
08-12 Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 MT
1 day+3.07%
1 week+11.56%
Current month+2.13%
1 month-1.90%
3 months+12.00%
6 months-10.89%
Current year-1.26%
1 week 16.17
Extreme 16.17
17.72
1 month 15.18
Extreme 15.18
19.09
Current year 12.07
Extreme 12.07
29.23
1 year 12.07
Extreme 12.07
29.23
3 years 1.64
Extreme 1.64
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 55 24/07/2022
Chief Executive Officer 81 31/03/2020
Director of Finance/CFO 48 01/04/2024
Director TitleAgeSince
Chairman 81 31/01/2020
Director/Board Member 48 30/11/2019
Director/Board Member 55 10/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
04/06/26 Buy

Chief Executive Officer

100,000 0.0129%
04/06/26 Buy

Chief Executive Officer

100,000 0.0129%
04/06/26 Buy

Chief Financial Officer

50,000 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
+3.07%+11.56%-19.41%+854.14% 13.37B
+4.16%+3.42%+49.37%+94.17% 74.16B
-0.37%-3.81%+19.75%+78.12% 57.39B
+1.63%-1.61%+3.83%+36.89% 47.64B
+0.50%+2.94%+344.62%+722.17% 44.29B
+3.05%-1.80%+28.78%+34.51% 42.5B
+1.00%-1.46%+5.17%+111.90% 40.71B
-0.54%+2.41%+9.31%+58.85% 30.97B
+1.56%+3.75%+31.34%+29.14% 28.53B
+0.76%-1.45%-7.44%-11.12% 24.34B
Average +1.48%+1.03%+46.53%+200.88% 40.39B
Weighted average by Cap. +1.60%-0.01%+55.50%+161.01%

Financials

2026 *2027 *
Net sales 2.94M 3.88M 3.46M 3.23M 5.53M 374M 5.57M 38.97M 15.16M 191M 14.57M 14.25M 613M 41.88M 55.37M 49.4M 46.02M 78.87M 5.33B 79.46M 556M 216M 2.72B 208M 203M 8.75B
Net income -701M -926M -826M -770M -1.32B -89.21B -1.33B -9.3B -3.62B -45.53B -3.48B -3.4B -146B -743M -982M -876M -816M -1.4B -94.61B -1.41B -9.87B -3.84B -48.29B -3.69B -3.61B -155B
Net Debt -470M -621M -554M -516M -885M -59.84B -892M -6.24B -2.43B -30.54B -2.33B -2.28B -98.16B -200M -265M -236M -220M -377M -25.48B -380M -2.66B -1.03B -13.01B -993M -972M -41.81B
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
05/10/26 US$17.27 +3.07% 5,266,393
02/10/26 US$16.76 +0.39% 5,196,190
01/10/26 US$16.69 -1.30% 7,900,981
30/09/26 US$16.91 +3.17% 13,060,430
29/09/26 US$16.39 +5.88% 27,339,973
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
13.06GBP
Average target price
22.51GBP
Spread / Average Target
+72.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SMMT Stock